UK Set to Raise Minimum Age for Puberty Blocker Clinical Trial to 11

Minimum age of 11 set for UK – Following a period of review, the UK has established a new minimum age of 11 for children participating in a clinical trial evaluating the use of puberty-blocking drugs. This decision, announced in February 2026, comes after the Medicines and Healthcare products Regulatory Agency (MHRA) expressed concerns about the safety of these medications for younger participants. Initially, the trial had no set age limit, but the MHRA suggested increasing the threshold to 14. The updated guidelines now set 11 for birth-registered female participants and 12 for birth-registered males, reflecting a more nuanced approach to eligibility.

Pause and Safeguards

The Pathways Trial, which aims to assess the physical, social, and emotional effects of puberty-suppressing hormones on young people, was temporarily halted in early 2026. This pause allowed for enhanced safeguards to be implemented, including the revised age criteria. Researchers from King’s College London, who are leading the trial, have committed to recruiting participants only after August 1, giving legal proceedings time to unfold. This adjustment is intended to address concerns raised by critics, particularly regarding informed consent and the long-term impacts of the drugs.

Puberty blockers, also referred to as puberty suppressing hormones (PSH), are used to delay or prevent the onset of puberty in individuals questioning their gender identity. The drugs have been a subject of debate since 2024, when they were banned for use in people under 18. The ban followed a 2024 review by Dr. Hilary Cass, who highlighted gaps in evidence supporting their use. Despite this, the MHRA has now endorsed the trial as a critical step in ensuring the safety and efficacy of these treatments for younger patients.

Legal Challenges and Ethical Concerns

Ongoing legal action by some clinicians and advocacy groups has cast a shadow over the trial’s progress. These parties argue that the study’s design lacks sufficient safeguards, particularly in relation to the potential effects on fertility and long-term health. They claim that children may not fully comprehend the implications of the treatment, raising questions about the ethics of the trial. The MHRA, however, asserts that the new age limits and additional measures will mitigate these risks.

“It is vital that the trial for puberty blockers in under-16s proceeds, or we’ll be left with ongoing charlatans handing out inappropriate drugs,” stated Dr. Hilary Cass. Her 2024 review, which led to the temporary ban on puberty blockers for under-18s, identified a lack of robust evidence for their use. Despite this, Cass emphasized the importance of clinical trials in validating the treatments, especially given the growing number of children accessing gender services.

The trial, approved by UK regulators and ethics experts in November 2025, is designed to include children under 16 who experience gender distress. It will examine how these drugs affect their overall wellbeing, including physical development, social interactions, and emotional health. Researchers stress that the trial’s design remains largely unchanged, though they have strengthened patient information and eligibility criteria to ensure transparency.

Eligibility and Consent Requirements

Participants in the trial must now meet additional criteria beyond the minimum age. These include demonstrating a clear understanding of the treatment’s potential benefits and risks, as well as obtaining parental consent. The MHRA has also introduced clearer guidance on when to discontinue the drugs, particularly if there are concerns about bone density, brain function, or vaginal bleeding. This includes detailed information on fertility preservation methods, which will be provided to participants and their families.

While the MHRA acknowledges the trial’s importance, it admits that the design and conduct of the study have not undergone major changes. Researchers from King’s College London say they welcome scrutiny, particularly as the trial aims to provide evidence-based insights into the use of puberty blockers for gender-affirming care. The updated age requirements and additional safeguards are intended to align the trial with current safety standards.

Legal challenges continue as campaigners push for stricter regulations. They argue that the MHRA’s decision to approve the trial overlooks the potential for long-term harm, especially to fertility. The ongoing litigation targets the MHRA, the government, and other stakeholders involved in the trial’s planning. Critics also point to the private sale of puberty blockers, particularly online, as evidence of rushed implementation without adequate oversight.

Context and Implications

Since the 2024 ban, the use of puberty blockers for children under 18 has been restricted, though some clinics continue to prescribe them. The Pathways Trial is seen as a key opportunity to evaluate the safety and effectiveness of these medications in a structured, evidence-based setting. By setting a minimum age of 11 and introducing age-specific criteria, the MHRA seeks to balance the needs of gender-questioning children with the necessity of rigorous clinical evaluation.

Dr. Cass’s review, which found “shaky foundations” in the evidence for gender medicine, has been a catalyst for these changes. While she initially advocated for a ban, she now supports the trial as a way to address gaps in knowledge. The trial’s findings could influence future guidelines on the use of puberty blockers, potentially leading to more personalized approaches for young patients. However, the debate over informed consent and long-term safety is far from over.

With recruitment set to begin in August, the trial marks a pivotal moment in the UK’s approach to gender-affirming treatments for children. The MHRA’s decision reflects a growing emphasis on safety, yet it also highlights the challenges of balancing medical innovation with ethical considerations. As the trial progresses, it will be crucial to monitor its outcomes and ensure that all participants, regardless of age, receive comprehensive care and support.